Methotrexate in Retinal Detachment With Proliferative Vitreoretinopathy

Methotrexate as an Adjunct to Parsplana Vitrectomy for the Preventing and Treatment of Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment: A Clinical Study

The aim of this study is to evaluate the efficacy and safety of intraocular methotrexate (MTX) in preventing and managing proliferative vitreoretinopathy (PVR) in patients undergoing retinal detachment surgery

Patients will be randomized into two groups if clinical evidence of PVR is detected at the time of surgery, utilizing a computer-generated list for randomization. All surgeries will be conducted by the same surgeon to maintain consistency in technique.

Intervention Groups:

1. Group 1 (PPV Alone): Patients in this group will undergo pars plana vitrectomy (PPV) only.

Group 2 (PPV with Methotrexate): Patients in this group will receive complete PPV along with adjunctive intravitreal methotrexate.

Inclusion Criteria:

• Patients aged 18 years and older.
• Diagnosed with RRD with clinical signs of PVR.
• No history of prior ocular surgeries for RRD or PVR.

Exclusion Criteria:

• Patients with other retinal diseases (e.g., diabetic retinopathy or retinal vascular occlusions).
• Individuals with significant systemic illnesses that could influence surgical outcomes.